Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...